Literature DB >> 25339301

Epstein-Barr virus-negative diffuse large B-cell lymphoma hosts intra- and peritumoral B-cells with activated Epstein-Barr virus.

Christiane Stuhlmann-Laeisz1, Monika Szczepanowski, Alisa Borchert, Monika Brüggemann, Wolfram Klapper.   

Abstract

Although the vast majority of diffuse large B-cell lymphomas (DLBCL) are negative for the Epstein-Barr virus (EBV), a subset of DLBCL in immunocompetent patients carries EBV in the lymphoma cells and expresses EBV-encoded RNA and/or proteins. EBV-positive DLBCL are rare and represent either pyothorax associated DLBCL or EBV-positive DLBCL of the elderly. In all cases of EBV-positive DLBCL, EBV is detectable in virtually all lymphoma cells, indicating that EBV was present at an initial phase of lymphomagenesis. We identified four lymphomas with an unusual EBV expression pattern. The majority of B-cell blasts were EBV-negative, but accompanied by a small number (less than 10 % of all B-cells) of EBV-positive B-cells with blastic morphology. The median age of the patients was 56.5 years, and no clinically evident immunosuppression was reported. In one patient EBV-positive blasts occurred in the gastric mucosa which resembled an EBV-positive mucocutaneous ulcer. In all cases EBV-positive B-cells occurred in small loose clusters within or adjacent to an EBV-negative DLBCL. In one case we were able to study immunoglobulin gene rearrangement in microdissected EBV-positive B-cells and the EBV-negative lymphoma compartment. This revealed different rearrangement patterns in EBV-negative DLBCL than in EBV-positive peritumoral B-cells, without clonal relationship between these B-cell populations. Despite the molecular data being limited to one patient, we suggest that in close proximity to EBV-negative DLBCL intra- and peritumoral EBV-positive B-cells may occur, possibly due to local immune escape mechanisms. This represents a diagnostic pitfall.

Entities:  

Mesh:

Year:  2014        PMID: 25339301     DOI: 10.1007/s00428-014-1661-z

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  24 in total

Review 1.  Persistence of the Epstein-Barr virus and the origins of associated lymphomas.

Authors:  David A Thorley-Lawson; Andrew Gross
Journal:  N Engl J Med       Date:  2004-03-25       Impact factor: 91.245

2.  Multiple cytokine- and chemokine-producing primary testicular diffuse large B-cell lymphoma, not otherwise specified.

Authors:  Shoko Nakayama; Taiji Yokote; Kazuki Iwaki; Yuji Hirata; Uta Nishiwaki; Toshikazu Akioka; Takuji Miyoshi; Yuki Masuda; Motomu Tsuji; Toshiaki Hanafusa
Journal:  Leuk Res       Date:  2012-05-30       Impact factor: 3.156

Review 3.  Senile Epstein-Barr virus-associated B-cell lymphoproliferative disorders: a mini review.

Authors:  Yoshie Shimoyama; Takashi Oyama; Naoko Asano; Aya Oshiro; Ritsuro Suzuki; Yoshitoyo Kagami; Yasuo Morishima; Shigeo Nakamura
Journal:  J Clin Exp Hematop       Date:  2006-03

4.  Isolation of Epstein-Barr virus (EBV)-negative cell clones from the EBV-positive Burkitt's lymphoma (BL) line Akata: malignant phenotypes of BL cells are dependent on EBV.

Authors:  N Shimizu; A Tanabe-Tochikura; Y Kuroiwa; K Takada
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

5.  Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma.

Authors:  Stefan D Dojcinov; Girish Venkataraman; Stefania Pittaluga; Iwona Wlodarska; Jeffrey A Schrager; Mark Raffeld; Robert K Hills; Elaine S Jaffe
Journal:  Blood       Date:  2011-03-08       Impact factor: 22.113

6.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.

Authors:  Christine P Hans; Dennis D Weisenburger; Timothy C Greiner; Randy D Gascoyne; Jan Delabie; German Ott; H Konrad Müller-Hermelink; Elias Campo; Rita M Braziel; Elaine S Jaffe; Zenggang Pan; Pedro Farinha; Lynette M Smith; Brunangelo Falini; Alison H Banham; Andreas Rosenwald; Louis M Staudt; Joseph M Connors; James O Armitage; Wing C Chan
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

Review 7.  Age-related Epstein-Barr virus-associated B-cell lymphoproliferative disorders: special references to lymphomas surrounding this newly recognized clinicopathologic disease.

Authors:  Yoshie Shimoyama; Kazuhito Yamamoto; Naoko Asano; Takashi Oyama; Tomohiro Kinoshita; Shigeo Nakamura
Journal:  Cancer Sci       Date:  2008-04-21       Impact factor: 6.716

8.  Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients.

Authors:  Takashi Oyama; Kazuhito Yamamoto; Naoko Asano; Aya Oshiro; Ritsuro Suzuki; Yoshitoyo Kagami; Yasuo Morishima; Kengo Takeuchi; Toshiyuki Izumo; Shigeo Mori; Koichi Ohshima; Junji Suzumiya; Naoya Nakamura; Masafumi Abe; Koichi Ichimura; Yumiko Sato; Tadashi Yoshino; Tomoki Naoe; Yoshie Shimoyama; Yoshikazu Kamiya; Tomohiro Kinoshita; Shigeo Nakamura
Journal:  Clin Cancer Res       Date:  2007-09-01       Impact factor: 12.531

9.  Epstein-Barr virus-positive diffuse large B-cell lymphoma in elderly patients is rare in Western populations.

Authors:  Sylvia Hoeller; Alexandar Tzankov; Stefano A Pileri; Philip Went; Stephan Dirnhofer
Journal:  Hum Pathol       Date:  2009-11-13       Impact factor: 3.466

10.  Senile EBV+ B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients.

Authors:  Takashi Oyama; Koichi Ichimura; Ritsuro Suzuki; Junji Suzumiya; Koichi Ohshima; Yasushi Yatabe; Takio Yokoi; Masaru Kojima; Yoshikazu Kamiya; Hirofumi Taji; Yoshitoyo Kagami; Michinori Ogura; Hidehiko Saito; Yasuo Morishima; Shigeo Nakamura
Journal:  Am J Surg Pathol       Date:  2003-01       Impact factor: 6.394

View more
  4 in total

1.  CD5 positivity is an independent adverse prognostic factor in elderly patients with diffuse large B cell lymphoma.

Authors:  Wen-Yu Chuang; Hung Chang; Lee-Yung Shih; Po-Nan Wang; Yu-Sun Chang; Tung-Liang Lin; Yu-Shin Hung; Chi-Ju Yeh; Shir-Hwa Ueng; Tzung-Chih Tang; Ming-Chung Kuo; Po Dunn; Jin-Hou Wu; Hsiao-Wen Kao; Che-Wei Ou; Yung-Liang Wan; Chuen Hsueh
Journal:  Virchows Arch       Date:  2015-09-14       Impact factor: 4.064

2.  Prognostic significance of Epstein-Barr virus DNA detection in pretreatment serum in diffuse large B-cell lymphoma.

Authors:  Akinao Okamoto; Masamitsu Yanada; Hiroki Miura; Yoko Inaguma; Masutaka Tokuda; Satoko Morishima; Tadaharu Kanie; Yukiya Yamamoto; Shuichi Mizuta; Yoshiki Akatsuka; Tetsushi Yoshikawa; Yoshikazu Mizoguchi; Shigeo Nakamura; Masataka Okamoto; Nobuhiko Emi
Journal:  Cancer Sci       Date:  2015-10-07       Impact factor: 6.716

3.  Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression.

Authors:  Sean I Tracy; Thomas M Habermann; Andrew L Feldman; Matthew J Maurer; Ahmet Dogan; Usha S Perepu; Sergei Syrbu; Stephen M Ansell; Carrie A Thompson; George J Weiner; Grzegorz S Nowakowski; Cristine Allmer; Susan L Slager; Thomas E Witzig; James R Cerhan; Brian K Link
Journal:  Haematologica       Date:  2017-11-23       Impact factor: 9.941

4.  Lymphomas associated with Epstein-Barr virus infection in 2020: Results from a large, unselected case series in France.

Authors:  Marie Donzel; Maxime Bonjour; Jean-Damien Combes; Florence Broussais; Pierre Sesques; Alexandra Traverse-Glehen; Catherine de Martel
Journal:  EClinicalMedicine       Date:  2022-10-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.